Blood Marker Flags Lymphoma Relapse Risk After CAR T
Researchers at Cornell and Dana-Farber link a pretreatment blood measure to how large B-cell lymphoma progresses after CAR T-cell therapy.
Updated on Nov. 18, 2026 in Cancer

A study published in Cell Reports Medicine on November 18, 2026, by Cornell and Dana-Farber researchers linked a pretreatment blood marker to lymphoma progression after CAR T-cell therapy. Patients who scored high on a plasma gene-activity measure had an 80% lower risk of cancer progression than those who scored low.
Why it matters
Nearly half of patients receiving anti-CD19 CAR T-cell therapy either fail to respond or relapse within a year, so a pretreatment marker that tracks risk could help identify patients whose tumor environment is linked to poorer outcomes. The finding requires validation in larger studies at other institutions before it could inform treatment decisions.
The analysis covered 91 lymphoma patients treated at Dana-Farber, with patients scoring above the median surviving longer within each of three groups receiving the same CAR T-cell product. The study does not yet show whether acting on the score would change outcomes, and validation in larger cohorts remains pending.
The players
Dana-Farber Cancer Institute
A Boston-based cancer center affiliated with Harvard Medical School that treated the patients in the study.
Cornell University
A private Ivy League research university whose researchers led the study alongside Dana-Farber.
The details
Researchers examined cell-free RNA, fragments of genetic material that cells release into the bloodstream, in pretreatment plasma samples from three groups of patients who received the same CAR T-cell product. The RNA score showed no significant correlation with lactate dehydrogenase before chemotherapy, suggesting it captures information beyond a standard marker.
Timeline
Nov. 18, 2026: Study published in Cell Reports Medicine.
Health Landscape
The study extends earlier biopsy research showing that lymphoma patients tended to fare better when the cells around their tumors resembled the environment inside a lymph node. Testing whether a blood-based version of that signal can predict CAR T outcomes would mark a shift toward less invasive prognostic tools in this treatment area.
For patients facing CAR T-cell therapy, a pretreatment blood test could eventually help flag who is at higher risk of relapse. Any clinical use would depend on validation in larger studies before changing how care is planned.
The takeaway
A simple pretreatment blood measure may someday help clinicians anticipate which lymphoma patients are most likely to progress after CAR T-cell therapy. Patients should discuss their own risk factors with their oncology team rather than acting on early research.
Further reading
For related coverage, see more on Cancer.
Source note: This article includes information reported by Fingerlakes1.






